{"id":"nac-bromhexine-bmx","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset (nausea, dyspepsia)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Rash or allergic reactions"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"N-acetylcysteine (NAC) is a mucolytic agent that breaks disulfide bonds in mucoproteins, reducing sputum viscosity and facilitating expectoration, while also providing antioxidant protection. Bromhexine is a secretolytic agent that increases mucus production and ciliary activity to enhance mucociliary clearance. Together, they improve airway clearance and reduce inflammation in respiratory conditions.","oneSentence":"NAC and bromhexine work synergistically to reduce mucus viscosity and promote clearance while providing antioxidant and anti-inflammatory effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:19.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) with mucus hypersecretion"},{"name":"Acute respiratory infections with excessive mucus production"},{"name":"Bronchiectasis"}]},"trialDetails":[{"nctId":"NCT04928495","phase":"PHASE3","title":"Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19","status":"UNKNOWN","sponsor":"Universidade Federal do Ceara","startDate":"2021-07-15","conditions":"COVID-19","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NAC + Bromhexine (BMX)","genericName":"NAC + Bromhexine (BMX)","companyName":"Universidade Federal do Ceara","companyId":"universidade-federal-do-ceara","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NAC + Bromhexine (BMX) is being studied as a potential treatment for COVID-19 in a clinical trial. The mechanism of action of Bromhexine is currently unknown, but it is classified as a small molecule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}